Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of HZN-825 (fipaxalparant) in idiopathic pulmonary fibrosis
jRCT2031220586Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of fipaxalparant in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change in FVC % predicted from baseline to Week 52. Started Jan 2023; status: completed.
02
Drugs
fipaxalparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2031220586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220586.